Mycoplasma genitalium
General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.
Overview
A sexually transmitted bacterium without a cell wall.
Infections
Urethritis, cervicitis, pelvic inflammatory disease; a cause of persistent or recurrent urethritis.
Signs and symptoms
Urethral or vaginal discharge, dysuria, pelvic pain; often no symptoms.
Antibiotic and antimicrobial resistance
Macrolide resistance is widespread and fluoroquinolone resistance is increasing.
Treatment considerations
Doxycycline followed by moxifloxacin, or resistance-guided therapy per CDC guidelines.
Infection control and public health
Partner evaluation and treatment.
Sources
- CDC. Mycoplasma genitalium (STI Treatment Guidelines).
- CDC. Sexually Transmitted Infections Treatment Guidelines, 2021.
Sources accessed November 2026. Links open external sites that InnovexLab does not control.
Medical disclaimer
This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.
Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.